Market closed
Lyra Therapeutics/$LYRA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lyra Therapeutics
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Ticker
$LYRA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
88
Website
LYRA Metrics
BasicAdvanced
$13M
-
-$1.52
-0.04
-
Price and volume
Market cap
$13M
Beta
-0.04
52-week high
$6.79
52-week low
$0.16
Average daily volume
942K
Financial strength
Current ratio
3.641
Quick ratio
3.452
Long term debt to equity
151.904
Total debt to equity
171.318
Management effectiveness
Return on assets (TTM)
-42.29%
Return on equity (TTM)
-186.18%
Valuation
Price to revenue (TTM)
8.897
Price to book
0.65
Price to tangible book (TTM)
0.65
Price to free cash flow (TTM)
-0.162
Growth
Revenue change (TTM)
3.37%
Earnings per share change (TTM)
22.12%
3-year revenue growth (CAGR)
371.88%
3-year earnings per share growth (CAGR)
-18.80%
What the Analysts think about LYRA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lyra Therapeutics stock.
LYRA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LYRA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lyra Therapeutics stock?
Lyra Therapeutics (LYRA) has a market cap of $13M as of February 26, 2025.
What is the P/E ratio for Lyra Therapeutics stock?
The price to earnings (P/E) ratio for Lyra Therapeutics (LYRA) stock is 0 as of February 26, 2025.
Does Lyra Therapeutics stock pay dividends?
No, Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Lyra Therapeutics dividend payment date?
Lyra Therapeutics (LYRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyra Therapeutics?
Lyra Therapeutics (LYRA) has a beta rating of -0.04. This means that it has an inverse relation to market volatility.